deVera Imelda E, Katz Jonathan E, Agus David B
Center for Applied Molecular Medicine at Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Clin Adv Hematol Oncol. 2006 Jul;4(7):541-9.
The lack of effective surrogates or biomarkers for biologic and disease state is a major hindrance to effective cancer care. Many laboratories have been using mass spectrometry as the means to discover new biomarkers. The success of these efforts relies on effective collaboration between clinicians and mass spectroscopists. This review describes many of the common proteomic experimental methodologies and evaluates the current state of proteomics-based biomarker discovery--starting from sample collection through sample processing and ultimately sample measurement. Guidelines are given for the evaluation of experimental design and for the gauging of result significance. Particular emphasis is placed on those aspects strongly associated with reproducibility from both clinical and laboratory perspectives.
缺乏针对生物制剂和疾病状态的有效替代指标或生物标志物是有效癌症治疗的主要障碍。许多实验室一直将质谱分析作为发现新生物标志物的手段。这些努力的成功依赖于临床医生和质谱分析人员之间的有效合作。本综述描述了许多常见的蛋白质组学实验方法，并评估了基于蛋白质组学的生物标志物发现的现状——从样本采集到样本处理，最终到样本测量。给出了实验设计评估和结果显著性评估的指导原则。特别强调了从临床和实验室角度来看与可重复性密切相关的那些方面。
